Last 487.60
Change Today 0.00 / 0.00%
Volume 0.0
RDHL On Other Exchanges
Symbol
Exchange
OTC US
NASDAQ CM
As of 7:24 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

redhill biopharma ltd (RDHL) Snapshot

Open
$486.90
Previous Close
$484.20
Day High
$493.50
Day Low
$485.00
52 Week High
02/27/14 - $524.00
52 Week Low
07/8/13 - $322.00
Market Cap
426.4M
Average Volume 10 Days
61.4K
EPS TTM
$-0.19
Shares Outstanding
87.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REDHILL BIOPHARMA LTD (RDHL)

Related News

No related news articles were found.

redhill biopharma ltd (RDHL) Related Businessweek News

No Related Businessweek News Found

redhill biopharma ltd (RDHL) Details

RedHill Biopharma Ltd., a biopharmaceutical company, acquires and develops late clinical-stage, proprietary formulations, and combinations of existing drugs. It develops therapeutic candidates primarily for the treatment of inflammatory and gastrointestinal diseases, including cancer and related conditions. The company’s pipeline includes six clinical stage therapeutic candidates, including RHB-101, a once-daily oral formulation of carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once-daily controlled release oral formulation of ondansetron for the prevention of chemotherapy and radiotherapy induced nausea and vomiting; and RHB-103, an oral thin film formulation of rizatriptan to treat acute migraine headaches. Its pipeline also consists of RHB-104, an oral combination therapy that is in Phase III clinical study for the treatment of Crohn's disease; RHB-105, an oral combination therapy, which is in Phase III clinical study to treat for Helicobacter pylori infection; and RHB-106, an encapsulated formulation for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.

8 Employees
Last Reported Date: 02/25/14
Founded in 2009

redhill biopharma ltd (RDHL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

redhill biopharma ltd (RDHL) Key Developments

Redhill Biopharma Announces Positive European Scientific Advice Meeting Regarding Rhb-102 and Plans to Submit A European Marketing Application

RedHill Biopharma Ltd. announced that it had concluded a positive European scientific advice meeting with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) regarding RHB-102, a proprietary, extended-release (once-daily) oral pill formulation of the anti-emetic oncology support drug ondansetron for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting. In light of the positive feedback from the UK MHRA, RedHill intends to submit, during the second half of the year, a Marketing Authorization Application (MAA) in Europe with the UK as the reference EU member state for the European Mutual Recognition Procedure (MRP). To support the planned MAA submission, RedHill has commenced a comparative bioavailability study comparing RHB-102 to the European reference drug. The two-arm crossover comparative bioavailability study includes 20 healthy volunteers and is intended to explore the relative bioavailability between RHB-102 and GlaxoSmithKline's European reference drug. The secondary objective of the study is to further assess the safety and tolerability of RHB-102. The company anticipates that the results of the bioavailability study will be available by July 2014. Subject to the results of the study and to the required regulatory process, and in light of the data from prior successful clinical studies conducted with RHB-102, the Company plans to submit a European MAA during the second half of 2014. In parallel to pursuing the current indications, RedHill is also pursuing a new undisclosed indication for RHB-102. The company has received guidance from the MHRA with regard to this additional indication, and is planning to commence a Phase III clinical study with RHB-102 in the U.S. later this year to support a potential future submission of marketing applications in the U.S. and Europe. RedHill expects that, if the marketing applications are approved, the new indication would significantly expand the potential market for RHB-102.

RedHill Biopharma Ltd. Presents at 8th Annual BIO Europe Spring 2014, Mar-10-2014

RedHill Biopharma Ltd. Presents at 8th Annual BIO Europe Spring 2014, Mar-10-2014 . Venue: OVAL Lingotto, Turin, Italy.

RedHill Biopharma Ltd. Provides Update on RHB-102 Development and Intellectual Property

RedHill Biopharma Ltd. reported that it has secured direct rights from Temple University to the original RHB-102 patents, a once-daily oral formulation of the anti-emetic drug ondansetron. The new licensing agreement with Temple University is unde similar financial terms as the previous agreement with SCOLR, which has been terminated by RedHill. The company also reported that, following the completion of several previously-announces clinical studies, a pre-New Drug Application ('NDA') meeting was held with the U.S. Food and Drug Administration ('FDA') regarding RHB-102's development for chemotherapy and radiotherapy-induced nausea and vomiting ('CINV' and 'RINV' respectively). Following the pre-NDA meeting, and in light of the FDA's feedback, RedHill provided the FDA with additional information and is currently awaiting the FDA's response. Given the ongoing discussions with the FDA, the Company believes that the NDA for RHB-102 will not be submitted in the first quarter of 2014 as planned. RedHill will provide an update on the expected timeline for NDA submission of RHB-102 as soon as sufficient regulatory clarity is obtained, based on the outcome of the discussions with the FDA. In parallel to pursuing the CINV and RINV indications, RedHill is also pursuing a new indication for RHB-102. The Company expects that, if approved by the FDA, the new indication would significantly expand the potential market for RHB-102. To support the submission of an NDA targeting this additional new indication, RedHill is planning a Phase III clinical study later this year. In parallel to advancing the regulatory pathways in the U.S. for multiple indications, RedHill also plans to submit, later this year, a Marketing Authorization Application ("MAA") for RHB-102 in Europe for CINV and RINV. RedHill plans to conduct a comparative bioavailability study comparing RHB-102 to a European reference product ahead of the MAA submission.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDHL:IT 487.60 0.00

RDHL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RDHL.
View Industry Companies
 

Industry Analysis

RDHL

Industry Average

Valuation RDHL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REDHILL BIOPHARMA LTD, please visit www.redhillbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.